Coya Therapeutics annual r&d spending
2021
2022
2023
2024
2025
Coya Therapeutics R&D Spending Growth & History (COYA)
Coya Therapeutics's r&d spending was $16.7M for fiscal 2025.
View full Coya Therapeutics company overviewCoya Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $16.7M | $4.9M | +41.03% |
| 2024 | 2024-12-31 | $11.9M | $6.4M | +115.68% |
| 2023 | 2023-12-31 | $5.5M | $1.1M | +24.68% |
| 2022 | 2022-12-31 | $4.4M | $1.9M | +73.57% |
| 2021 | 2021-12-31 | $2.5M | — | — |
Coya Therapeutics quarterly r&d spending
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.0M | $1.4M | +37.33% |
| Q1 2026 | 2026-03-31 | $4.1M | −$1.1M | −21.43% |
| Q4 2025 | 2025-12-31 | $4.9M | $3.0M | +155.00% |
| Q3 2025 | 2025-09-30 | $2.9M | $692,972 | +31.16% |
| Q2 2025 | 2025-06-30 | $3.7M | −$903,049 | −19.78% |
| Q1 2025 | 2025-03-31 | $5.2M | $2.1M | +66.15% |
| Q4 2024 | 2024-12-31 | $1.9M | $327,809 | +20.37% |
| Q3 2024 | 2024-09-30 | $2.2M | $631,671 | +39.67% |
| Q2 2024 | 2024-06-30 | $4.6M | $3.5M | +327.56% |
| Q1 2024 | 2024-03-31 | $3.1M | $1.9M | +154.78% |
| Q4 2023 | 2023-12-31 | $1.6M | $901,599 | +127.34% |
| Q3 2023 | 2023-09-30 | $1.6M | $313,943 | +24.56% |
| Q2 2023 | 2023-06-30 | $1.1M | −$379,421 | −26.21% |
| Q1 2023 | 2023-03-31 | $1.2M | $252,908 | +25.84% |
| Q4 2022 | 2022-12-31 | $708,032 | — | — |
| Q3 2022 | 2022-09-30 | $1.3M | — | — |
| Q2 2022 | 2022-06-30 | $1.4M | — | — |
| Q1 2022 | 2022-03-31 | $978,804 | — | — |
Coya Therapeutics r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Coya Therapeutics's r&d spending increased from $2.5M to $16.7M, a change of $14.2M. The latest reported quarter, Q2 2026, shows $5.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Coya Therapeutics source filings ↗